Thomas Gajewski, M.D., Ph.D.


Fields, P., Gajewski, T.F., and Fitch, F.W. Blocked Ras activation in anergic CD4+ T cells. Science. 271:1276-1278. 1996.

Fallarino, F., Uyttenhove, C., Boon, T., and Gajewski, T.F. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156:1095-1100. 1996.

Bird, J.J., Brown, D.R., Mullen, A.C., Moskowitz, N.H., Gajewski, T.F., Wang, C.-R., and Reiner, S.L. Helper T cell differentiation is controlled by the cell cycle. Immunity. 9:229-237. 1998.

Wan, Y.Y., Leon, R.P., Marks, R., Cham, C.M., Schaack, J., Gajewski, T.F., and DeGregori, J. Transgenic expression of the coxsackie/adenovirus receptor (CAR) enables adenoviral mediated gene delivery in naive T cells. Proc.Natl.Acad.Sci.USA. In Press. 2000.

Fallarino, F., Uyttenhove, C., Boon, T., and Gajewski, T.F. Improved efficacy of dendritic cell vaccines, and successful immunization with tumor antigen peptide-pulsed PBMC, by co-administration of rmIL-12. Int. J. Cancer. 80:324-333. 1999.

Kacha, A.K., Fallarino, F., Markiewicz, M.A., and Gajewski, T.F. Cutting Edge: Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J.Immunol. In Press. 2000

Gajewski, T.F., Fallarino, F., Ashikari, A. and Sherman, M.L. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous PBMC plus rhIL-12. Clin. Cancer Res. In Press. 2000.